Surrozen, Inc./DE

SRZN · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
106
SEC Filings

Business Summary

PART I . Overview We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair. Our current strategic focus is ophthalmology, where Wnt signaling plays a central role in retinal vascular integrity, barrier function, and tissue maintenance. We are located in South San Francisco, California. Our mission is to transform the treatment of serious ophthalmic disease by fully exploiting the Wnt pa...

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSRZNdiscussed_in_filing Cybersecurity
topic_mentionSRZNdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-232025-12-310001193125-26-119818EDGAR89K words
2025-03-312024-12-310000950170-25-047712EDGAR—
2024-04-102023-12-310000950170-24-043399EDGAR—
2023-03-312022-12-310000950170-23-011118EDGAR—
2022-03-282021-12-310000950170-22-004787EDGAR—
2021-03-312020-12-310001104659-21-044518EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001193125-25-272422EDGAR62K words
2025-08-082025-06-300000950170-25-105847EDGAR—
2025-05-092025-03-310000950170-25-068046EDGAR—
2024-11-062024-09-300000950170-24-122318EDGAR—
2024-08-122024-06-300000950170-24-095443EDGAR—
2024-05-082024-03-310000950170-24-055706EDGAR—
2023-11-082023-09-300000950170-23-061150EDGAR—
2023-08-092023-06-300000950170-23-040648EDGAR—
2023-05-102023-03-310000950170-23-020618EDGAR—
2022-11-142022-09-300000950170-22-025096EDGAR—
2022-08-112022-06-300000950170-22-016889EDGAR—
2022-05-112022-03-310000950170-22-009343EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001193125-26-119757EDGAR3K words
2026-01-300001193125-26-031798EDGAR—
2025-11-070001193125-25-272363EDGAR—
2025-10-170001193125-25-242518EDGAR—
2025-08-290000950170-25-112253EDGAR—
2025-08-080000950170-25-105839EDGAR—
2025-05-150000950170-25-072696EDGAR—
2025-05-090000950170-25-068011EDGAR—
2025-03-310000950170-25-047702EDGAR—
2025-03-280000950170-25-046769EDGAR—

106 total filings indexed. 78 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001824893
TickerSRZN
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: fb890e557209c513562797df34e944d99292fde6afcf2f6b20ef7966fc0ebfb2
parent: fc91057645a28bd4e6d51fba664251f5694dec53715bc777511a8dc26efbc6ff
content hash: ebcc509edcf9a34ff63b241f050cb4beff8689ed46209737251deab7c63e36d1
signed: 2026-04-13T04:47:36.282Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf